After 3 weeks of open-label administration of transdermal estradiol ( 100 g/d ) , participants were randomized to a parallel design to receive either estradiol ( 100 g/d ; 27 participants ) or matched placebo skin patches ( 29 participants ) for 3 additional weeks under double-blind conditions .